Last reviewed · How we verify
s.c. injection
This drug targets the PD-1 receptor to modulate the immune response.
This drug targets the PD-1 receptor to modulate the immune response. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | s.c. injection |
|---|---|
| Also known as | Depigoid(R)Birch, placebo, Placebo |
| Sponsor | Leti Pharma GmbH |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, it prevents the interaction with its ligands, PD-L1 and PD-L2, thereby releasing the brakes on T-cell activation and proliferation. This leads to an enhanced anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Diarrhea
- Fatigue
- Nausea
- Cough
- Pruritus
- Rash
- Hypertension
- Decreased appetite
Key clinical trials
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (PHASE2)
- Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (PHASE4)
- Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy (PHASE3)
- Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (PHASE2)
- Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors (PHASE3)
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD (PHASE3)
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- s.c. injection CI brief — competitive landscape report
- s.c. injection updates RSS · CI watch RSS
- Leti Pharma GmbH portfolio CI